Physician profile
Robert B Carlin
NPI 1942368949
$1,920.48
in general payments reported to CMS, 2019-2025
14 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $171 · 2021: $344 · 2022: $103 · 2023: $243 · 2024: $319 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $848.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $602.36 | 2020-2023 | |
| Janssen Biotech, INC. | $457.34 | 2023-2025 | Tremfya, Simponi, Stelara |
| Biofrontera INC. | $424.95 | 2019 | |
| Revance Therapeutics, INC. | $126.91 | 2024-2025 | Daxxify |
| Amgen INC. | $78.74 | 2023-2024 | Otezla |
| Novartis Pharmaceuticals Corporation | $58.04 | 2022-2025 | |
| Genzyme Corporation | $44.08 | 2024 | |
| Leo Pharma INC. | $25.66 | 2020 | |
| Abbvie INC. | $25.23 | 2025 | |
| Incyte Corporation | $24.10 | 2021 | |
| Galderma Laboratories, L.P. | $17.35 | 2019 | |
| Boston Scientific Corporation | $15.57 | 2024 | Wavewriter Alpha Prime 16 |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.76 | 2019 | |
| Epi Health, LLC | $8.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Carlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.